Did You See This in The Annual Report?

[anonymous]

My cousin is studying finance in college and he had to study a company for one of his classes. He used Aytu’s annual report and found this. Does anyone know how it will impact us?

Teva
On December 21, 2018, the Company and Teva entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla under an abbreviated new drug application (“ANDA”) filed by Teva beginning on July 1, 2026, or earlier under certain circumstances. The ANDA was approved by the FDA on June 19, 2020.

Actavis
On October 17, 2017, the Company entered into an agreement granting Actavis a non-exclusive license to certain patents owned by the Company by which Actavis has the right to manufacture and market its generic version of Adzenys under its ANDA beginning on September 1, 2025, or earlier under certain circumstances. The ANDA was approved by the FDA on June 22, 2023.

 

[anonymous]

It means that your drugs are going generic and you better have something else to sell or the company is going under

 

[anonymous]

Not to worry though. Boy genius GP will use the Ayty connect scam to save the day

 

[anonymous]

My cousin had another question for his financial class about Aytu. He found out that Adzenys costs $381 at CVS, but if a person has insurance, and the insurance company doesn’t pay for it, the person pays $50. He said that CVS has to buy it for like $360 from Aytu and Aytu has to reimburse CVS. He said Aytu loses at least $310 on this prescription. Plus they have other costs like manufacturing and shipping Adzenys. Does anyone know how we make money if we are losing over $300 on this prescription? He said it doesn’t make any sense to him and I couldn’t explain it.

 

[anonymous]

Good luck to your cousin to try to figure this one out. Aytu loses a lot of money on each prescription if the insurance company doesn’t pay for it